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Abstract
Introduction: A strong biologic rationale exists for targeting markers of endothelial cell (EC) activation as clinically
informative biomarkers to improve diagnosis, prognostic evaluation or risk-stratification of patients with sepsis.
Methods: The objective was to review the literature on the use of markers of EC activation as prognostic
biomarkers in sepsis. MEDLINE was searched for publications using the keyword ‘sepsis’ and any of the identified
endothelial-derived biomarkers in any searchable field. All clinical studies evaluating markers reflecting activation of
ECs were included. Studies evaluating other exogenous mediators of EC dysfunction and studies of patients with
malaria and febrile neutropenia were excluded.
Results: Sixty-one studies were identified that fulfilled the inclusion criteria. Overall, published studies report
positive correlations between multiple EC-derived molecules and the diagnosis of sepsis, supporting the critical role
of EC activation in sepsis. Multiple studies also reported positive associations for mortality and severity of illness,
although these results were less consistent than for the presence of sepsis. Very few studies, however, reported
thresholds or receiver operating characteristics that would establish these molecules as clinically-relevant
biomarkers in sepsis.
Conclusions: Multiple endothelial-derived molecules are positively correlated with the presence of sepsis in
humans, and variably correlated to other clinically-important outcomes. The clinical utility of these biomarkers is
limited by a lack of assay standardization, unknown receiver operating characteristics and lack of validation.
Additional large-scale prospective clinical trials will be required to determine the clinical utility of biomarkers of
endothelial activation in the management of patients with sepsis.
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Introduction
Sepsis is a complex syndrome that results from a
host’s response to invasive infection [1,2], and severe
sepsis with organ dysfunction and septic shock are
leading causes of death in critically ill patients [3]. A
tool that would predict prognosis or allow risk-stra-
tification of patients is needed to inform healthcare
providers, families and decision makers, and facili-
tate the study and implementation of evolving thera-
peutic interventions.
A biomarker is defined as “...a characteristic that is
objectively measured as an indicator of normal
biological processes, pathogenic processes or pharmaco-
logic responses to therapeutic intervention” [4]. Despite
the proposal of over 100 distinct biological molecules as
biomarkers for sepsis, no useful single biomarker, or
combination thereof, has yet been identified [5].
A hallmark of sepsis is a change in microvascular
function. Widespread endothelial damage and apoptosis
appears to be directly involved (see Figure 1), with
numerous associations observed between sepsis and
endothelial cell (EC) activation [6-10]. Consequently,
there is a strong biologic rationale for targeting markers
of endothelial activation as biomarkers of sepsis. A large
number of EC-active molecules have been investigated
as potential biomarkers for the early diagnosis, triage
and prognostication of sepsis. These include regulators
of endothelial activation, such as vascular endothelial
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growth factor (VEGF), endocan and the angiopoeitin
pathway (Ang-1/2), adhesion molecules such as s-
ICAM-1, sVCAM-1, and sE-selectin-1), mediators of
permeability and vasomotor tone (s-Flt and endothelin-
1); and mediators of coagulation (vWF, ADAMTS13).
Given the potential for, and growing interest in, EC-
derived molecules as biomarkers in sepsis, we conducted
a systematic review of the current published literature of
biomarkers to determine their performance in predicting
the severity of sepsis and clinical outcomes. This sys-
tematic review will serve as an update and supplement
to other recent reviews in the literature [5,11-14], given
the rapidly evolving nature of the field.
Materials and methods
Data sources
We systematically and inclusively identified all studies
evaluating markers of endothelial activation, (including
angiopoietins and sTie2R, sVEGF and sFlt-1, sICAM-1,
sVCAM-1, sE-selectin, endothelin-1, endocan, VWF and
ADAMTS13) in sepsis. We electronically searched
MEDLINE (1950 to Week 2, September 2011) and
EMBASE (1980 to Week 37, 2011) databases for all per-
tinent English language studies. (Please see Additional
file 1, Search Strategy).
Study selection methods
Study selection was performed independently by three
reviewers (KX, SM, JMS), with disagreements resolved
through arbitration by a fourth reviewer (WCL). A
study was included if it (1) studied adult patients with
sepsis or the systemic inflammatory response syndrome
(SIRS), or studied patients at risk for sepsis or SIRS, and
(2) evaluated a clinical endpoint (the development of
sepsis, sepsis severity, development of organ dysfunction
or mortality). Studies of patients less than 18 years of
age, patients with febrile neutropenia, patients with
malaria, interventional clinical trials studying a specific
Figure 1 Endothelial activation induces increased production of adhesion molecules such as ICAM-1, VCAM-1, E-selectin and P-
selectin. E-selectin induces leukocyte rolling, and ICAM-1 and VCAM-1 bind leukocyte function antigen 1 (LFA1) and very late antigen 4 (VLA4),
respectively, to induce firm leukocyte adhesion. Activation is partially mediated by VEGF binding to VEGF receptor 1 (VEGFR1, also known as Flt-
1) and VEGF receptor 2 (VEGFR2). Soluble Flt-1 binds VEGF competitively to render an anti-inflammatory response in the setting of sepsis. Ang-1
is constitutively secreted by pericytes and smooth muscle cells. Upon activation, Ang-2 is rapidly released by Weibel-Palade bodies, competitively
interfering with Ang-1/Tie2 signaling and thereby increasing expression of adhesion molecules.
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intervention or medication and case reports were
excluded.
Study data extraction and analysis
For each of the selected studies, we extracted the bio-
marker(s) evaluated, study size and patient population,
and details of the primary and secondary outcomes.
Outcomes of interest for each biomarker were tabulated
and compared across studies where appropriate. Study
design, standardization of sepsis definition and other
methodological data were extracted and each study was
subject to the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) system for
assessing the quality of evidence [15]. Due to the antici-
pated broad study heterogeneity and disparate study
outcomes, we did not attempt to numerically combine
or perform a meta-analysis of study results.
Results
Our search identified 1,243 unique articles (see Fig-
ure 2). A total of 84 studies met our predefined
inclusion and exclusion criteria, of which a further 23
studies were excluded after retrieval of full-text publi-
cation for the following reasons: 14 studies did not
report a clinical outcome [16-29], 4 studies did not
include a relevant patient population [30-32], 3 stu-
dies were interventional trials [33-35], and 2 studies
were not in English and the English abstracts pro-
vided insufficient information to allow adjudication of
study inclusion [36,37]. The remaining 61 studies
were included in our review.
All studies were observational designs, including second-
ary analyses of data collected during prospective clinical
trials. Most studies used standard consensus definitions of
sepsis. Interpretation of the magnitude of effect or associa-
tion between biomarkers and sepsis or clinical outcomes
was limited by a lack of standardization in individual bio-
marker assays, an absence of identified or validated thresh-
olds or cut-points in individual biomarker levels, and a
lack of reported odds ratios or relative risk. Several studies
identified positive associations between biomarker levels
and severity of sepsis (for example, sepsis, severe sepsis
and septic shock), but given the aforementioned limita-
tions and heterogeneity across studies in this association,
we did not deem this to be sufficient evidence of a dose-
response association to upgrade the quality level of these
studies given the aforementioned limitations. Conse-
quently, all studies were assigned a GRADE level of ‘low
quality’ with respect to the association between individual
biomarker levels and sepsis [15].
Figure 2 Study flow diagram.
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The Angiopoietin system
We identified 11 studies investigating angiopoietin 2
(Ang-2) as a biomarker in human sepsis (see Table 1-
Studies Evaluating Angiopoietin-2). All but one were
prospective observational studies [38-44], with one sec-
ondary analysis of a previously conducted cohort study
[45].
Association with sepsis
Seven studies evaluated the association between Ang-2
levels and sepsis, reporting higher levels of Ang-2 in
patients with sepsis compared to patients without sepsis
in the ward setting [43,44], the ICU [38,40,42,45], and
patients with acute lung injury/acute respiratory distress
syndrome (ALI/ARDS) [45]. Ang-2 levels were also
higher in sepsis than in either patients with sterile SIRS
[40] or healthy controls [41]. Kumpers et al. also
reported that Ang-2 concentrations were elevated in all
ICU patients (irrespective of sepsis status) compared to
healthy controls [42]. One study found that patients
who did not have SIRS/sepsis on admission but subse-
quently developed SIRS/sepsis, had significant increases
in Ang-2 over time [40].
There were inconsistent reports of the association
between Ang-2 and the severity of sepsis (as defined by
sepsis, severe sepsis and septic shock), with one positive
study [44] and four studies that failed to observe a con-
sistent correlation [38,39,41,42]. Higher levels of Ang-2
were also reported in patients with severe sepsis com-
pared to septic ICU patients without organ dysfunction
[38,43,44], non-septic hospitalized controls [43,44], and
ICU patients without SIRS [38].
None of the studies identified a cut point or threshold
of circulating Ang-2 that allowed differentiation of
patients with sepsis and without sepsis, or stratification
of patients with respect to sepsis severity based on base-
line or serial serum Ang-2 concentrations.
Association with clinical outcome
Three studies [39,40,42] observed associations between
circulating Ang-2 levels and severity of illness as defined
by Acute Physiology and Chronic Health Evaluation II
(APACHE II) [46] or Sequential Organ Failure Assess-
ment score (SOFA) [47], and five studies reported a
relationship between increasing Ang-2 levels and
increasing mortality [39-42,48]. Kumpers et al. found
that circulating Ang-2 levels were independently asso-
ciated with 30-day survival after adjustment for
APACHE II score, SOFA score and serum lactate levels
[42]. Kranidioti et al. found that Ang-2 concentrations
were associated with sepsis-related mortality at baseline
and every day for the first seven days in ICU, and Ang-2
levels greater than 9.7 ng/mL were associated with a
three-fold increased risk of sepsis-related mortality [41].
Siner et al. found higher Ang-2 levels were associated
with hospital motality, and the patient cohort could be
stratified for hospital mortality by admission Ang-2
levels [39]. Ricciuto et al. observed that serial measure-
ments of Ang-2 were associated with 28-day mortality
and multiple organ dysfunction (MOD) score [48].
One study found Ang-2 was independently associated
with the severity of lung injury as measured by pulmon-
ary leak, and was predictive for the development of
ARDS [45]. A second study found an inverse correlation
between Ang-2 and PaO2/FiO2 ratio [49]. Page et al.
found that the Ang-2/Ang-1 ratio was significantly
increased in patients with invasive streptococcal infec-
tion who developed toxic shock syndrome, compared to
those with uncomplicated infection [50].
The leukocyte adhesion pathway
We identified 19 studies investigating sICAM-1 as a
sepsis biomarker (see Table 2-Studies evaluating
sICAM), 12 studies for sVCAM-1 (see Table 3-Studies
Evaluating sVCAM-1), 23 studies for sE-selectin-1
(Table 4-Studies Evaluating sE-selectin-1), and 2 studies
for endocan (see Table 5-Studies Evaluating Endocan).
All were prospective studies or secondary analyses of
prospective studies. These studies focused on emergency
room patients with suspected infections or shock
[51,52], and critically ill patients admitted to intensive
care units, including medical and surgical patients
[51,53-76], patients with ventilator-associated pneumo-




All studies comparing sICAM-1 in septic patients and
healthy controls reported higher levels in septic patients
[54,55,58,59,65,66,68]. sICAM-1 was also found to be
significantly higher in sepsis than in patients with
trauma [61,62,66,67], postoperative patients [55],
patients with other forms of shock [52], and non-septic
ICU patients [59,66,68]. One study reported that
sICAM-1 levels were similar in septic patients and ICU
patients without sepsis [65]. Two studies explicitly com-
pared sICAM-1 in patients with sepsis and SIRS [53,68],
but only one found higher sICAM-1 in sepsis [53]. Sev-
eral studies observed that baseline sICAM-1 levels were
similar in non-septic patients and healthy controls
[55,59,66].
The association between sICAM-1 levels and sepsis
severity was variable. Seven studies investigated this
association, with four studies reporting higher sICAM-1
levels with increasing severity of sepsis [59,64,68,77] and
three negative studies [53,61,65].
Association with clinical outcome
Eleven studies reported data on mortality. Five of these
studies reported that increasing sICAM-1 levels
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Table 1 Studies evaluating angiopoietin-2
Study Year N Population Standard Criteria for SIRS/
Sepsis
Association with Sepsis Other Outcomes
Parikh et al.,
[43]
2006 51 ICU patients with sepsis
(22) and hospitalized
controls (29)
2003 ACCP/SCCM [2] Ang-2 higher in patients severe sepsis than patients
with sepsis and controls (23.2 vs. 4.8 and 3.5 ng/mL




2008 112 Mechanically ventilated
patients, with sepsis (24)
and without (88)
1992 ACCP/SCCM [1] Ang-2 higher in patients with sepsis than without sepsis
(4.1 vs. 0.4 ng/mL; P < 0.01)
Higher Ang-2 associated with ALI/ARDS (P < 0.001)
and higher in ARDS than in ALI (P > 0.001);
Independently associated with the severity of
pulmonary leak (r = 0.41; P = 0.014).
Orfanos
et al., [38]
2007 61 ICU patients 1992 ACCP/SCCM [1] Ang-2 higher in severe sepsis compared to patients
without SIRS or sepsis (P < 0.05 by analysis of variance)
Ang-2 levels correlated with levels of circulating




2008 60 Trauma patients admitted
to ICU (54) and healthy
controls (6)
2003 ACCP/SCCM [2] Ang-2 higher in sepsis and severe sepsis than in healthy
controls, or trauma patients with sterile SIRS (P < 0.05);
Predictive of sepsis/severe sepsis (P = 0.017, 0.002
respectively); Increases in serial Ang-2 predicted
development of sepsis (P < 0.05)
Ang-2 correlated with 28-day survival (P = 0.015)
Kumpers
et al., [42]
2008 72 Patients admitted to
medical ICU (43) and
healthy controls (29)
2003 ACCP/SCCM [2] Ang-2 higher in septic patients than in patients without
sepsis (16.5 vs. 2.8 ng/mL; P < 0.001); Not correlated
with severity of sepsis (median Ang-2 16.5 vs. 28.1 ng/
mL; P = 0.12);
Ang-2 correlated with mortality (P = 0.001)
Davis et al.,
[44]
2010 124 Patients admitted to a
mixed ICU
1992 ACCP/SCCM [1] Ang-2 higher in patients with severe sepsis compared to
patients with sepsis without organ failure and non-
septic controls (12.4 vs. 6.1 and 2.7 ng/mL, respectively;
P < 0.0001).
Ang-2 not predictive of 28-day mortality (P = 0.32)
Siner et al.,
[39]
2009 66 Patients admitted to ICU 1992 ACCP/SCCM [1] Ang-2 not correlated with severity of sepsis Ang-2 correlated with mortality (P = 0.02)
Ricciuto
et al. [48]
2011 70 Patients with severe sepsis 1992 ACCP/SCCM [1] Admission levels of Ang-2 and Ang-2/Ang-1 ratio
were not associated with 28-day mortality Serially
measured Ang-2 levels correlated directly with the
MOD score (P = .003)
Ebihara
et al. [49]




1992 ACCP/SCCM [1] Positive correlation between Ang-1 and PaO2/FiO2
ratio (r = 0.427; P < 0.001) Inverse correlation




2011 37 16 invasive streptococcal
infection and toxic shock
21 invasive steptococcal
infection alone
S. pyogenes isolated from
normally sterile site and 2009
Consensus definition of
streptococcal toxic shock
Ang-2:Ang-1 ratio increased in Streptococcal Toxic Shock
Syndrome compared to those with uncomplicated
invasive streptococcal infection (P < 0.05)
Kranidoti
et al., [41]




2003 ACCP/SCCM [1] Ang-2 higher in septic patients compared to healthy
controls. (P < 0.001)
Ang-2 correlated with mortality (P < 0.05); Ang-2
levels greater than 9.7 ng/mL associated with
sepsis-related mortality (OR = 3.3; P = 0.033)
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory Distress Syndrome; ED, emergency department; MOF,












Table 2 Studies evaluating sICAM
Study Year N Population Standard Criteria for
SIRS/Sepsis
Associations with sepsis Other outcomes
Shapiro et al., [51] 2010 221 ED patients with sepsis without organ
dysfunction (71), severe sepsis
without shock (66), septic shock (71),
and non-infected controls (13)
1992 ACCP/SCCM [1] sICAM-1 elevated in septic shock compared
with non-infected controls (P < 0.05);
sICAM-1 associated with increasing sepsis
severity P < 0.05; modest correlation with SOFA
and APACHE-II; predicts mortality and severe
sepsis (AUC of 0.72 (95% CI 0.57 to 0.87), 0.61
(95% CI 0.53 to 0.69))
Schuetz et al., [52] 2011 161 Patients with hypotension: 69 sepsis
35 cardiac 12 hemorrhagic 12
unknown
Clinical classification
based on clinical and
microbiological data
ICAM-1 higher in sepsis compared to non-sepsis
(P < 0.05)
Hofer et al., [55] 2009 147 Surgical ICU patients with severe
sepsis (101) and major abdominal
surgery (28), and healthy controls (18)
2003 ACCP/SCCM [2] sICAM-1 higher in the septic group than
postoperative and volunteer groups at diagnosis
(444.7 ng/ml vs 213.7 ng/ml and 219.6 ng/ml,
respectively; P < 0.001)
Not predictive of mortality at the time of
diagnosis of sepsis, but non-survivors had trend
to higher sICAM-1 levels at 48 h and 120 h
(683.2 vs 434.1 ng/ml, P = 0.067; 360.2 vs 467.8
ng/ml, P = 0.083, respectively) compared to
survivors




Higher in sepsis than controls (2.56 ug/ml vs
0.19 ug/ml; P < 0.05)
Scherpereel et al.,
[53]
2006 90 ICU patients with sepsis (63), SIRS (7),
healthy controls (20)
1992 ACCP/SCCM [1] sICAM-1 higher in sepsis compared to SIRS P <
0.02
sICAM-1 not predictive of mortality or severity
of sepsis
Kinoshita et al., [56] 2002 56 Gram negative sepsis from intra-
abdominal infection admitted to
surgical ICU (47), healthy controls (9)
1992 ACCP/SCCM [1] sICAM-1 higher in sepsis than healthy controls Not correlated with mortality in those with
ARDS; Higher in those with ARDS than those
without P < 0.05
Paterson et al., [57] 2000 16 ICU patients with SIRS (10), healthy
controls (6)
1992 ACCP/SCCM [1] sICAM-1 not reported in healthy controls Not correlated with mortality
Weigand et al., [58] 1999 21 Surgical ICU patients with septic
shock (14), healthy controls (7)
1992 ACCP/SCCM [1] sICAM-1 significantly higher in sepsis than
controls (P < 0.05)
sICAM-1 significantly higher in nonsurvivors
than survivors, sensitivity and specificity for
cutoff of 800 ng/ml was 74.1%
Froon et al., [73] 1998 42 ICU patients with sepsis and VAP 1992 ACCP/SCCM [1] sICAM-1 higher in VAP patients complicated by
severe sepsis or septic shock than other VAP
patients, but statistical significance not achieved
Not predictive of mortality, and correlates
poorly with SAPS-II (r = 0.16, P = 0.30)
Kayal et al., [59] 1998 41 ICU patients with severe sepsis or
septic shock (25), ICU controls (7),
healthy controls (9)
1992 ACCP/SCCM [1] sICAM-1 higher in septic patients than in
noninfected ICU controls and healthy volunteers
(P < 0.0001); higher in septic shock than those
without septic shock (P < 0.05)
sICAM-1 correlated with mortality; correlated













Table 2 Studies evaluating sICAM (Continued)
Boldt et al., [60] 1997 30 Surgical ICU patients with post-
operative sepsis (30), healthy controls
(not stated)
1992 ACCP/SCCM1 sICAM-1 higher in septic patients than healthy
controls
Higher in older than younger patients P < 0.05,
and tends to increase in older patients and
decrease in younger patients over time
Egerer et al., [61] 1997 24 ICU patients with infection (8), severe
sepsis (16)
1992 ACCP/SCCM [1] sICAM-1 higher in severe sepsis compared with
patients with infection (P > 0.05)
Not correlated with mortality in patients with
severe sepsis




sICAM-1 level higher in septic than trauma
patients (987.7 vs 472.1 ng/ml; P = 0.0002)
sICAM-1 correlated with endotoxin, TNF-a, IL-6,
IL-8, Type II PLA2 (Type II phospholiaps A2), NO
(P < 0.05 for all)
Boldt et al., [63] 1996 30 Surgical ICU patients with
postoperative sepsis (15), trauma (15)
1992 ACCP/SCCM [1] sICAM-1 higher in sepsis than trauma (1,266 vs
444 ng/ml; P < 0.01)
Endo et al., [64] 1996 28 ICU patients with sepsis with MOF (8),




sICAM-1 higher in septic patients with or
without MOF than patients with MOF but no
infection (1103.3 vs 356.0 ng/ml, and 862.5 vs
356.0 ng/ml, respectively, P < 0.05))
sICAM-1 level higher in septic patients with
MOF than those without (P = 0.0401)




sICAM-1 higher in septic patients than trauma
and controls (573 vs 148 and 235 ng/ml,
respectively, P < 0.001)
Nakae et al., [67] 1996 34 ICU patients with sepsis (21), trauma
(13)
1992 ACCP/SCCM [1] sICAM-1 higher in septic patients than in
trauma patients (987 vs 472 pg/ml; P = 0.0002)
sICAM-1 correlated with endotoxin, TNF-alpha
and IL-8 (P < 0.05 for all)
Sessler et al., [68] 1995 66 ICU patients with sepsis (25), SIRS
(25), ICU controls (4), healthy
volunteers (12)
1992 ACCP/SCCM [1] sICAM-1 higher in sepsis than ICU controls and
healthy controls (1,259 vs 585 ng/ml, P < 0.001;
1,259 vs 355 ng/ml, P < 0.0001); sICAM-1 is
higher in SIRS than ICU controls and healthy
controls (937 vs 585 ng/ml, P < 0.05; 937 vs 355
ng/ml, P < 0.001); higher in sepsis vs SIRS (1,259
vs 937 ng/ml; P = 0.12)
sICAM-1 elevated with increasing severity of
illness: septic shock, severe sepsis and sepsis
(1,551, 796, and 542 ng/ml, respectively, ANOVA
P = 0.017); correlated with cumulative MOF
score, shock severity score (r = 0.46, P = 0.021; r
= 0.50, P < 0.009); higher in nonsurvivors vs
survivors (1,697 vs 854 ng/ml; P = 0.0096)
Cowley et al., [65] 1994 125 ICU patients with sepsis (21), severe




sICAM-1 higher in severe sepsis, uncomplicated
sepsis, and ICU controls than healthy controls P
< 0.05.
sICAM-1 with no significant difference between
severe sepsis, uncomplicated sepsis and ICU
controls. Not correlated with mortality
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory Distress Syndrome; ED, emergency department; MOF,












Table 3 Studies evaluating sVCAM-1
Study Year N Population Standard Criteria
for SIRS/Sepsis
Association with sepsis Other outcomes
Shapiro et al., [51] 2010 221 ED patients with sepsis without organ
dysfunction (71), severe sepsis without
shock (66), septic shock (71), and non-
infected controls (13)
1992 ACCP/SCCM [1] sVCAM-1 elevated in septic shock compared
with non-infected controls (P < 0.05)
sVCAM-1 associated with sepsis severity P < 0.04;
predicts mortality and severe sepsis (AUC of 0.57
(95% CI 0.35 to 0.79), 0.60 (95% CI 0.52 to 0.69))
Hofer et al., [55] 2009 147 Surgical ICU patients with severe
sepsis (101), major abdominal surgery
(28), healthy controls (18)
2003 ACCP/SCCM [2] sVCAM-1 did not differentiate between
septic, postoperative and healthy controls
sVCAM-1 not predictive of mortality at the time of
diagnosis of sepsis, but nonsurvivors had elevated
sVCAM-1 at 48 h and 120 h compared to survivors
(1,275.1 vs 882.0 ng/ml, P = 0.027; 1,685.5 vs 748.5
ng/ml; P = 0.021, respectively)
Kinoshita et al., [56] 2002 56 Gram negative sepsis from intra-
abdominal infection admitted to
surgical ICU (47), healthy controls (9)
1992 ACCP/SCCM [1] sVCAM-1 higher in patients than healthy
controls
sVCAM-1 did not differentiate those with ARDS from
those without; not predictive of mortality in those
with ARDS
Presterl et al., [69] 1999 40 ICU patients with Candida (20) and
bacterial sepsis (20)
1992 ACCP/SCCM [1] At all times (days 1, 7, 14) sVCAM-1 levels
higher in Candida sepsis than bacterial
sepsis (P < 0.05)
sVCAM-1 not correlated with mortality
Knapp et al., [78] 1998 54 Patients with sepsis (28 gram positive,
11 gram negative), 15 healthy controls
1992 ACCP/SCCM [1] sVCAM-1 elevated in sepsis compared with
healthy controls (P < 0.05)
sVCAM-1 does not correlate with mortality in gram
positive sepsis; does not distinguish between gram
positive and gram negative sepsis
Boldt et al., [60] 1997 30 Surgical ICU patients with post-
operative sepsis (30), healthy controls
(not stated)
1992 ACCP/SCCM [1] sVCAM-1 higher in septic patients than
healthy controls
Higher in older than younger patients P < 0.05, and
tends to increase in older patients and decrease in
younger patients over time




sVCAM-1 higher in septic than trauma
patients (2,536 vs 1,019.0 ng/ml; P = 0.0004)
sVCAM-1 level correlated with TNF-a, IL-6, IL-8, NO,
sE-selectin-1 ((P < 0.05 for all)
Boldt et al., [63] 1996 30 Surgical ICU patients with
postoperative sepsis (15), trauma (15)
1992 ACCP/SCCM [1] sVCAM-1 is higher in sepsis than trauma
(1,042 vs 689 ng/ml; P < 0.05)
Endo et al., [64] 1996 28 ICU patients with sepsis with MOF (8),




sVCAM-1 higher in septic patients with or
without MOF than patients with MOF but
no infection (2,654.9 vs 945.0 ng/ml, P =
0.0295; 2,045.0 vs 945.0 ng/ml, P = 0.0037)
sVCAM-1 did not differ between septic patients with
and without MOF (2,654.9 vs 2,045.0 ng/ml; P =
0.1315)
Furian et al., [76] 2011 45 Patients admitted to ICU with severe
sepsis or septic shock
1992 ACCP/SCCM [1] sVCAM-1 not associated with left ventricular
function or size.
Schuetz et al., [52] 2011 161 Patients with hypotension: 69 sepsis,






VCAM-1 higher in sepsis compared to non-
sepsis (P < 0.05)
Cowley et al., [65] 1994 125 ICU patients with sepsis (21), severe




sVCAM-1 is higher in sepsis than controls sVCAM-1 higher in severe sepsis than
uncomplicated sepsis at baseline (P = 0.06) and
peak concentrations P < 0.01. Not correlated with
mortality
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory Distress Syndrome; ED, emergency department; MOF,












Table 4 Studies evaluating sE-selectin-1
Study Year N Population Standard Criteria for
SIRS/Sepsis
Association with sepsis Other outcomes
Schuetz et al., [52] 2011 161 Patients with hypotension: 69
sepsis, 35 cardiac, 12 hemorrhagic,
12 unknown
Clinical classification
based on clinical and
microbiological data
E-selectin higher in sepsis compared to non-
sepsis (P < 0.05) E-selectin independently
associated with sepsis after adjustment for age,
sex, blood pressure and mortality (P = 0.001) with
AUC of 0.74 for discrimination of sepsis and non-
sepsis
Shapiro et al., [51] 2010 221 ED patients with sepsis without
organ dysfunction (71), severe
sepsis without shock (66), septic
shock (71), and non-infected
controls (13)
1992 ACCP/SCCM [1] sE-selectin-1 levels elevated in septic shock
compared with non-infected controls
sE-selectin-1 associated with sepsis severity P <
0.001; predicts mortality and severe sepsis (AUC
of 0.65 (95% CI 0.49 to 0.82) and 0.71 (95% CI
0.64 to 0.78) respectively)




sE-selectin-1 elevated in sepsis compared to
reference value (190 ng/ml vs 55 ng/ml; P <
0.05))
Kinoshita et al., [56] 2002 56 Gram negative sepsis from intra-
abdominal infection admitted to
surgical ICU (47), healthy controls
(9)
1992 ACCP/SCCM [1] sE-selectin-1 does not differentiate between
ARDS from non ARDS
Not predictive of mortality in those with ARDS
Geppert et al., [74] 2000 32 ICU patients on day two post
successfulCPR (25), non-critically ill
controls (7)
1992 ACCP/SCCM [1] sE-selectin-1 higher in SIRS compared to controls
(96.2 ng/ml vs 42.8 ng/ml; P = 0.23), but does
not differentiate patients with SIRS vs patients
without SIRS
Higher in non-survivors than survivors (114.2 ng/
ml vs 85.7 ng/ml; P = 0.025)
Osmanovic et al.,
[72]
2000 27 ICU patients with sepsis with MOF
(9), healthy controls (18)
Clinical definition of
sepsis
sE-selectin-1 higher in sepsis compared to
healthy controls (118 vs 28.5 ng/ml; P < 0.001)
Hynninen et al., [70] 1999 20 ICU patients with severe sepsis
(11), severe acute pancreatitis (9)
1992 ACCP/SCCM [1] sE-selectin does not differentiation between
those with severe acute pancreatitis and severe
sepsis
Higher in those with higher SOFA scores (SOFA ≥
10, P = 0.043), but not correlated with mortality
Presterl et al., [69] 1999 40 ICU patients with candida (20)
and bacterial sepsis (20)
1992 ACCP/SCCM [1] sE-selectin-1 lower in patients with Candida
sepsis than bacterial sepsis (P < 0.05) on Day 1
Higher in non-survivors
Takala et al., [71] 1999 76 Hospitalized patients with sepsis
with organ failure (8) and without
organ failure (12); healthy controls
(56)
1992 ACCP/SCCM [1] sE-selectin-1 level elevated in septic patients
compared to healthy adults P < 0.001
Not correlated with organ failure
Weigand et al., [58] 1999 21 Surgical ICU patients with septic
shock (14), healthy controls (7)
1992 ACCP/SCCM [1] sE-selectin-1 higher in sepsis than healthy
controls (P < 0.05)
Not predictive of mortality or severity of disease
Froon et al., [73] 1998 42 ICU patients with sepsis and VAP 1992 ACCP/SCCM [1] sE-selectin-1 higher in patients with severe sepsis
or septic shock than other VAP patients, but
statistical significance not achieved
Day 2 sE-selectin-1 higher in nonsurvivors than
survivors (114.3 vs 67.0 ng/ml; P = 0.04);
Correlates poorly with SAPSII (r = 0.18, P = 0.25)
Kayal et al., [59] 1998 41 ICU patients with severe sepsis or
septic shock (25), ICU controls (7),
healthy controls (9)
1992 ACCP/SCCM [1] sE-selectin-1 higher in septic patients than
noninfected ICU controls and healthy volunteers
(p < 0.0001); higher in those with septic shock
than those without (p < 0.05)
sE-selectin-1 higher in nonsurvivors than survivors
on day 0 (286 vs 195 ng/ml; P < 0.05), but
decreases after Day 3 of sepsis to reach a level
similar to that of survivors Day 14; correlated with












Table 4 Studies evaluating sE-selectin-1 (Continued)
Knapp et al., [78] 1998 54 Patients with sepsis (28 gram
positive, 11 gram negative), 15
healthy controls
1992 ACCP/SCCM [1] sE-selectin-1 higher in septic patients than
controls p < 0.05
sE-selectin-1 higher in nonsurvivors than survivors
of gram positive sepsis on day 0, 4 and 7 (175 vs
85 ng/ml, P < 0.01; 155.7 vs 78.8 ng/ml, P < 0.05;
180 vs 76.1 ng/ml, P < 0.001, respectively); does
not differentiate gram positive from gram
negative infections.
Boldt et al., [60] 1997 30 Surgical ICU patients with post-
operative sepsis (30), healthy
controls (not stated)
1992 ACCP/SCCM [1] sE-selectin-1 higher in septic patients than
healthy controls
Higher in older than younger patients P < 0.05,
and tends to increase in older patients and
decrease in younger patients over time
Cummings et al.,
[79]
1997 119 ICU patients with sepsis (67), SIRS
(44), ICU controls (8)
1992 ACCP/SCCM [1] sE-selectin-1 higher in culture positive sepsis than
culture negative sepsis, SIRS and ICU controls
(15.39 vs 4.87, 2.33, and 1.97 ng/ml, respectively;
P < 0.0001)
Day 1 levels higher for nonsurvivors than
survivors (10.61 vs 4.35 ng/ml of log transformed
mean sE-selectin-1; P < 0.05); sE-selectin-1
correlates strongly to the degree of
hemodynamic compromise (P < 0.0001), and
moderately with the peak MOF score (r = 0.30, P
= 0.001)
Egerer et al., [61] 1997 24 ICU patients with infection (8),
severe sepsis (16)
1992 ACCP/SCCM [1] Higher in patients with severe sepsis and MOF
than those with infection alone (P < 0.05)
Higher in nonsurvivors than survivors on Day 7-8,
P < 0.05
Takakuwa et al., [62] 1997 34 ICU admissions with sepsis (20),
trauma (14)
No Standard Definition sE-selectin-1 higher in sepsis than trauma (287.9
vs 195.0 ng/ml; P = 0.0055)
sE-selectin-1 level correlated with TNF-a, IL-8,
Type II PLA2, sICAM-1 (P < 0.005 for all)
Boldt et al., [63] 1996 30 Surgical ICU patients with
postoperative sepsis (15), trauma
(15)
1992 ACCP/SCCM [1] sE-selectin-1 higher in sepsis than trauma (340 vs
57.9 ng/ml; P < 0.05)
Endo et al., [64] 1996 28 ICU patients with sepsis with MOF




sE-selectin-1 higher in septic patients with or
without MOF than patients with MOF but no
infection (345.2 vs 121.8 ng/ml, P = 0.0016; 266.2
vs 121.8 ng/ml, P = 0.0054)
sE-selectin-1 did not differ significantly between
septic patients with and without MOF (345.2 vs
266.2 ng/ml; P = 0.2939)
Moss et al., [66] 1996 55 ICU patients with sepsis (19),
trauma (36) controls (5)
Clinical diagnosis of
sepsis
Higher in sepsis than trauma and controls (573 vs
148 and 235 ng/ml, respectively, P < 0.001)
Simons et al., [75] 1996 50 Multiple trauma patients,
infectious complications in 14
Not specified sE-selectin-1 higher in patients who subsequently
developed infection, organ dysfunction, or both,
by 36 h. P = 0.08
sE-selectin-1 higher in non-survivors than
survivors (P = 0.0018)
Cowley et al., [65] 1994 125 ICU patients with sepsis (21),




sE-selectin higher in sepsis than controls (P <
0.01).
sE-selectin-1 higher in severe sepsis than
uncomplicated sepsis on presentation (P < 0.01)
and more pronounced with peak values (P <
0.001). Not correlated with mortality
Newman et al., [80] 1993 88 ICU patients with sepsis with




Higher in septic shock than controls (23.3 vs 0.92
ng/ml; P < 0.05); not elevated in uncomplicated
sepsis compared to controls
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory Distress Syndrome; ED, emergency department; MOF,












correlated with mortality [55,58,59,68,77], but six studies
found no such correlation [53,56,57,61,65,73]. One study
found a trend towards increased mortality with increas-
ing sICAM-1 levels over time [55].
Two studies evaluated the discriminative characteris-
tics of sICAM-1 [51,58]. Weigand et al. reported that a
sICAM-1 threshold of 800 ng/ml could differentiate
survivors from non-survivors with a sensitivity and
specificity of 74.1%, although this value was derived
from a small sample of 14 post-surgical patients with
relatively high mortality (50%) [58]. Shapiro reported
on a group of 221 patients presenting to the emer-
gency department with suspected infections, of which
208 had sepsis of varying severity. The presenting
sICAM-1 value predicted mortality with an area under
the receiver operating characteristic (ROC) curve of
0.72 (95% CI (0.57 to 0.870)). However, a cutoff value
was not reported [77].
Several studies reported moderate to poor correlation
of sICAM-1 with the degree of severity of illness or
number of organ failures as defined by APACHE II,
SOFA, Multiple Organ Failure Score and Simplified
Acute Physiology Score [59,68,73,77].
One study reported varying kinetics of sICAM-1
according to age: In 30 patients with postoperative sep-
sis, Boldt et al. reported that older patients had higher
sICAM-1 levels than younger patients (P < 0.05), and
sICAM-1 tended to increase over time in older patients
while decreasing over time in younger patients [60].
Soluble VCAM-1 (sVCAM-1)
We identified 12 studies evaluating sVCAM-1 (see Table
3-Studies Evaluating sVCAM-1) in sepsis. These studies
evaluated sVCAM-1 in emergency department patients
[51], postoperative patients [55,63], patients admitted to
ICU [56,62], critically-ill trauma patients [60] and
patients with sepsis [64,65,69,78]. Three studies
compared sVCAM-1 levels with healthy control groups
[55,65,78].
Association with sepsis
Six studies reported that sVCAM-1 levels were signifi-
cantly greater in patients with sepsis than in healthy
controls [65,78], trauma patients [62,63], non-infected
patients [77] and patients with multiple organ failure
due to causes other than sepsis [64]. Four studies
reported that sVCAM-1 levels effectively differentiated
septic from non-septic patients [62-64,77], but one
study reported sVCAM-1 levels were not significantly
different between septic patients, postoperative patients
and healthy controls [55]. One study reported higher
sVCAM-1 levels in patients with shock due to sepsis
compared to other forms of shock [52].
Three studies attempted to correlate sVCAM-1 with
increasing sepsis severity [64,65,77]. Shapiro et al. found
a moderate degree of correlation with severe sepsis with
an area under the ROC curve of 0.60 (95% CI 0.52 to
0.69) [77]. Cowley et al. reported that baseline and peak
values of sVCAM-1 were higher in ICU patients with
severe sepsis than in uncomplicated sepsis [65]. Conver-
sely, another study reported that sVCAM-1 was not dif-
ferent in septic patients with or without organ failure
[64].
Association with clinical outcome
Six of the 10 identified studies examined mortality out-
comes, with 2 studies reporting an association between
higher sVCAM-1 levels and mortality [55,77], and 4 stu-
dies showing no significant correlation with mortality in
patients with ARDS [56], gram-positive sepsis [78], and
septic patients admitted to ICU [65,69]. Hofer et al.
found no correlation between baseline sVCAM-1 and
mortality in septic patients but reported significantly
higher sVCAM-1 levels at 48 and 120 hours in non-sur-
vivors compared to survivors.
Table 5 Studies evaluating Endocan
Study Year N Population Standard
Criteria for
SIRS/Sepsis
Association with sepsis Other outcomes
Scherpereel
et al., [53]






Higher in sepsis than SIRS or healthy
controls (2.71 vs 0.77 and 0.68 ng/ml;
P < 0.001);higher in septic shock than
severe sepsis and uncomplicated sepsis
(6.11 vs 1.97 and 1.95 ng/ml;
P < 0.05, P < 0.02)
Endocan on ICU admission higher in
nonsurvivors than patients still alive after
10 days (6.98 vs 2.54 ng/ml; P < 0.01),
using a cutoff of 6.2 ng/ml, sensitivity and
specificity are 75% and 84% respectively.
Bechard
et al., [23]






Higher in septic shock than healthy
controls (7.815 vs 1.081 ng/ml; P = 0.0173)
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory
Distress Syndrome; ED, emergency department; MOF, Multiple Organ Failure; SAPS, Simplified Acute Physiology Score; SCCM, Society of Critical Care Medicine;
SIRS, Systemic Inflammatory Response Syndrome; SOFA, Sequential Organ Failure Assessment
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Only one study addressed correlation of sVCAM-1
with clinical severity scores, and reported modest corre-
lation with SOFA and APACHE II [77].
Two studies reported variability of sVCAM-1 in sepsis
across different patient populations [64,69]. Presterl et
al. investigated the difference of sVCAM-1 level in Can-
dida sepsis compared to bacterial sepsis, and found that
sVCAM-1 was higher in Candida sepsis at days 1, 7 and
14 [69]. Similar to sICAM-1, Endo et al. found higher
sVCAM-1 levels with increasing age, and observed that
the dynamics of serial sVCAM-1 were different in
patients stratified by age. Specifically, sVCAM-1 values
increased over the course of sepsis time in older patients
and decreased in younger patients [64].
One study found that sVCAM-1 was not associated
with left ventricular size or function in patients with
sepsis or septic shock [76].
Soluble E-selectin
Twenty-three studies were identified that evaluated sE-
selectin as a biomarker in sepsis (see Table 4-Studies
Evaluating sE-selectin-1).
Association with sepsis
The majority of identified studies reported higher levels
of sE-selectin in sepsis compared to healthy controls or
other patient groups without sepsis. Ten studies specifi-
cally reported significantly elevated sE-selectin levels in
sepsis when compared with healthy controls
[54,58,59,65,66,71,72,78-80]. Geppert et al. reported
higher sE-selectin levels in patients with SIRS following
cardiopulmonary resuscitation compared to controls
[74]. sE-selectin was also reported to be significantly
higher in septic patients compared to trauma patients
[62,63,66], ICU controls [59,79], patients with infection
but without systemic sepsis [61,77], patients with shock
from other causes [52], and patients with multiple organ
failure without infection [64]. Hynninen et al. concluded
that sE-selectin values were not statistically different in
patients with severe sepsis from those with severe acute
pancreatitis [70].
Association with clinical outcome
The reported association of sE-selectin and disease
severity has been inconsistent. Five studies showed a
correlation between the marker and increasing sepsis
severity [59,61,65,77,79], although three studies did not
find a significant correlation [64,71,73].
Thirteen of the identified studies evaluated the asso-
ciation between sE-selectin and mortality, with nine stu-
dies reporting a significant positive correlation
[59,61,69,73-75,77-79] and four studies reporting no
correlation [56,58,65,70]. Among the studies reporting
positive association, there was significant heterogeneity
in the strength and type of association. One study of
ICU patients with severe sepsis and septic shock
reported that baseline sE-selectin-1 levels were higher in
non-survivors than survivors, but the difference existed
only for the first three days of sepsis [59]. In contrast,
two other studies demonstrated a more persistent diver-
gence of sE-selectin-1 between survivors and non-survi-
vors of sepsis: Knapp et al. reported that sE-selectin-1
remained significantly elevated in non-survivors com-
pared to survivors throughout the first seven days of
sepsis [78], while Egerer reported that sE-selectin peaked
in survivors of sepsis on the second day and decreased
thereafter, whereas it continued to rise in patients who
subsequently died [61]. One other study found that sE-
selectin-1 predicted mortality in patients presenting to
the emergency department with suspected infections,
with an area under the ROC curve of 0.65 [51].
Only a few studies examined correlation between sE-
selectin-1 and clinical severity of illness scores, and
none found strong correlations. Shapiro et al. showed
that sE-selectin correlated modestly with SOFA and
APACHE-II [51]. Hynnien et al. reported that levels of
sE-selectin were higher in patients with a SOFA score ≥
10 compared to individuals with a score less than 10
[70]. sE-Selectin was also reported to correlate moder-
ately or poorly with SAPSII [59,73] and MOF score
[59,79].
Three studies evaluated variability in sE-selectin levels
in different patient groups [60,69,79]. Boldt et al.
showed sE-selectin levels in septic patients increased
across age groups [60]. Cummings et al. showed higher
levels in bacteremic sepsis than in non-bacteremic sepsis
[79], and Presterl et al. found higher levels of sE-selectin
in bacterial sepsis than in Candida sepsis [69].
Endocan
Two prospective observational studies were identified
evaluating endocan as a biomarker in sepsis [23,53] (see
Table 5-Studies Evaluating Endocan).
Association with sepsis
Both studies reported that serum endocan was increased
in septic patients. Schepereel et al. reported in their pro-
spective study that endocan levels were higher in
patients with sepsis than in patients with SIRS or
healthy controls [53]. Bechard et al. showed that endo-
can levels were higher in patients with septic shock than
in healthy controls [23].
Association with clinical outcome
Scherpereel et al. reported that mean endocan levels
were higher in patients with septic shock than in
patients with severe sepsis or sepsis. Furthermore, endo-
can levels measured at ICU admission were higher in
non-survivors than in patients who were alive at 10
days. Using a threshold of 6.2 ng/ml, the sensitivity and
specificity of endocan for predicting mortality were 75%
and 84% respectively [53].
Xing et al. Critical Care 2012, 16:R7
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Mediators of permeability and vasomotor tone
We identified seven studies that examined soluble VEGF
(see Table 6-Studies evaluating VEGF), two studies exam-
ining soluble FLT (Table 7-Studies Evaluating sFLT) and
four studies examining endothelin-1 as biomarkers in
sepsis (see Table 8-Studies Evaluating Endothelin-1). All
but two were prospective studies, with two secondary ana-
lyses of previously conducted cohort studies [45,81].
Patients recruited were emergency room patients with sus-
pected infection [51,77] or ICU patients [42,45,51,81-88].
Table 6 Studies evaluating VEGF
Study Year N Population Standard
criteria for SIRS/
sepsis
Association with sepsis Other outcomes
Shapiro
et al., [77]
2008 83 ED patients with septic shock
(17), suspected infection






VEGF levels higher in septic shock
and infected patients without shock
compared with non-infected
controls (P < 0.01)
VEGF correlated with APACHE-II
score at presentation (P = 0.01)
Karlsson
et al., [82]




VEGF levels higher in severe sepsis
compared with healthy controls at 0
and 72 h (P = 0.029, 0.003,
respectively)
VEGF lower in non-survivors at









VEGF levels lower in non-septic and
septic patients compared with
healthy controls (P < 0.0001)





2008 112 Mechanically ventilated




VEGF levels higher in patients with
sepsis than without sepsis (63.6 vs
20.7 pg/ml, P = 0.012)
VEGF trended higher in
patients compared with
controls (P = 0.268); No








VEGF levels elevated in sepsis
compared with healthy controls (134
vs 55 pg/ml, P < 0.001)




2011 101 81 pneumonia and septic




VEGF levels lower in septic shock vs.
pneumonia (P = 0.005)
Day 1 VEGF did not
discriminate survivors from
non-survivors (P = 0.46)
Rafat et al.,
[84]
2007 62 Medical ICU with sepsis (32),




VEGF levels elevated in septic
compared with non-septic patients
(1,351 vs 477 pg/ml, P < 0.01)
VEGF not correlated with
mortality (P < 0.48)
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory
Distress Syndrome; ED, emergency department; MOF, Multiple Organ Failure; SAPS, Simplified Acute Physiology Score; SCCM, Society of Critical Care Medicine;
SIRS, Systemic Inflammatory Response Syndrome; SOFA, Sequential Organ Failure Assessment
Table 7 Studies evaluating sFLT
Study Year N Population Standard criteria
for SIRS/sepsis
Association with sepsis Other outcomes
Schuetz
et al., [52]
2011 161 Patients with hypotension: 69






sFlt-1 higher in sepsis compared
to non-sepsis (P < 0.05) SFlt-1
independently associated with
sepsis after adjustment for age,
sex, blood pressure and mortality
(P = 0.03) with AUC 0.70 for




2008 83 ED patients with septic shock
(17), suspected infection





sFLT levels elevated with
worsening disease: non-infected,
suspected infection without
shock, septic shock (159, 386 and
551 ng/dL, respectively, P < 0.01)
sFLT correlated with APACHE-II,
SOFA scores upon presentation
and at 24 h (P < 0.05 for all)
Shapiro
et al., [51]
2010 221 ED patients with sepsis
without organ dysfunction
(71), severe sepsis without
shock (66), septic shock (71),
and non-infected controls (13)
1992 ACCP/SCCM [1] sFLT levels elevated in septic
shock compared with non-
infected controls (243 vs 41 ng/
ml, P < 0.001)
sFLT correlated with SOFA,
APACHE-II, lactate; Predicted
severe sepsis and mortality (AUC
of 0.82 (95% CI 0.76 to 0.88),
0.91 (95% CI 0.87 to 0.95))
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory
Distress Syndrome; ED, emergency department; MOF, Multiple Organ Failure; SAPS, Simplified Acute Physiology Score; SCCM, Society of Critical Care Medicine;
SIRS, Systemic Inflammatory Response Syndrome; SOFA, Sequential Organ Failure Assessment
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Soluble VEGF
Four studies reported a positive association with sepsis,
with higher levels in septic patients compared with non-
septic critically ill patients [77,83,84] and healthy con-
trols [82]. In contrast, Van der Heijden et al. did not
find a significant difference in soluble VEGF between
septic and non-septic ICU patients [45] and Kumpers et
al. reported lower serum VEGF levels in patients with
sepsis compared to healthy controls [42]. Van der Flier
et al. reported significantly elevated VEGF levels in non-
survivors compared with survivors [83], in contrast to
Karlsson et al. who reported significantly lower VEGF
levels in non-survivors [82].
Soluble FLT (sFlt)
Both studies reporting sFLT were prospective studies
from the same centre, studying emergency room
patients with suspected infections, with non-infected
patients serving as controls. There was some overlap
between the two studies, with some patients reported in
both cohorts. sFLT was shown to be elevated with
increasing severity of illness [77], and was also predictive
of severe sepsis and mortality, both upon presentation
and longitudinally during hospitalization [51].
Endothelin-1
Two studies reported that endothelin-1 was significantly
elevated in patients with sepsis compared with healthy
controls [86,87]. An additional two studies reported a
correlation with severity of illness as defined by other
biomarkers [85] or ACCP/SCCM criteria [81]. There
was no documented association between endothelin-1
levels and mortality in the one study that examined this
outcome [81].
Mediators of coagulation
We identified 14 relevant studies studying von Willeb-
rand Factor (vWF) and sepsis (see Table 9-Studies Eval-
uating von Willebrand Factor). All studies reported
assays of either VWF:Ag and/or VWF:RCo activity. Four
studies presented data on ADAMTS13 (see Table 10-
Studies Evaluating ADAMTS13), which reported either
ADAMTS13 antigen levels or ADAMTS13 activity.
Von Willebrand factor (vWF)
Association with sepsis
Eight studies examined the capability of circulating vWF
levels to differentiate patients with sepsis from patients
with other illnesses. Two studies found that vWF levels
were significantly higher in septic patients compared to
patients with systemic inflammation from other causes
[89,90], other non-septic critically-ill patients [45,53,90],
and healthy controls [59,89]. Two studies reported
higher levels in patients with sepsis than in patients
with SIRS or healthy controls, but the differences did
not reach statistical significance [91-93]. In a cohort of
patients with ALI/ARDS, Ware et al. reported that vWF
was significantly increased in septic patients compared
with those without sepsis (P < 0.05) [94].
Hovinga et al. in a secondary analysis of a clinical
trial, reported that vWF activity was significantly higher
in septic patients than in healthy controls, but vWF was
Table 8 Studies evaluating Endothelin-1
Study Year N Population Standard criteria for
SIRS/sepsis
Association with sepsis Other Outcomes
Schuetz
et al., [81]
2007 95 Consecutive ICU
admissions with SIRS,
sepsis, septic shock
1992 ACCP/SCCM [1] Endothelin-1 rises with sepsis,
septic shock, compared with SIRS
(64.3, 131.6, 23.1 pmol/L,
respectively; P < 0.01 between SIRS
and sepsis, P < 0.05 between sepsis
and septic shock)
Endothelin-1 not correlated with
mortality (p = 0.87)
Piechota
et al., [85]






Endothelin-1 correlates with CRP
and PCT levels as estimates of level
of sepsis severity (P < 0.05 for both)
Endothelin-1 correlates with SOFA
score (p < 0.001)
Weitzberg
et al., [86]
1991 16 Sepsis (6) and healthy
controls (10)
Bone et al., [102] Endothelin-1 elevated in sepsis
compared with healthy controls




2011 45 Patients admitted to
ICU with severe sepsis
or septic shock
1992 ACCP/SCCM [1] Endothelin-1 levels associated
with left ventricular and right
ventricular function. (p = 0.002)
Pittet
et al., [87]




Bone et al., [102] Endothelin-1 elevated in septic
patients compared with healthy
controls (19.9 vs 6.1 pg/ml, P <
0.0001)
Endothelin-1 inversely correlated
with cardiac index (p < 0.005);
correlated with APACHE-II scores
(p < 0.01)
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory
Distress Syndrome; ED, emergency department; MOF, Multiple Organ Failure; SAPS, Simplified Acute Physiology Score; SCCM, Society of Critical Care Medicine;
SIRS, Systemic Inflammatory Response Syndrome; SOFA, Sequential Organ Failure Assessment
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Table 9 Studies evaluting von Willebrands factor
Study Year N Population Standard criteria for SIRS/sepsis Association with sepsis Other outcomes
Claus et al., [89] 2009 63 ICU patients with severe sepsis (11),
non-elective cardiac surgery (22),
elective cardiac surgery as ICU
controls (24), and post-exercise as
healthy controls (6)
1992 ACCP/SCCM [1] VWF:Ag higher in patients with
sepsis and post non-elective cardiac
surgery than ICU controls (P < 0.05)




2008 57 ICU patients with sepsis (11), non-
elective cardiac surgery (22), and
elective cardiac surgery as ICU
controls (24)
Not specified VWF:Ag higher in sepsis and in non-
elective cardiac surgery than ICU
controls (both P < 0.001)




2008 112 Mechanically ventilated patients,
with sepsis (24) and without (88)
1992 ACCP/SCCM [1] VWF higher in patients with sepsis
than without sepsis (P < 0.001)
VWF correlated with mortality (P =
0.006); VWF higher in those with ALI/
ARDS than those without (P < 0.001)
Hovinga et al.,
[95]
2007 80 Medical and surgical ICU patients
with severe sepsis or septic shock
(40), and healthy controls (40)
1992 ACCP/SCCM [1] VWF:Ag and VWF:RCO higher in
sepsis than controls (P < 0.001)
VWF not correlated with disease severity,
organ dysfunction, or mortality
Martin et al., [91] 2007 89 ICU patients with severe sepsis (30),
sepsis-unrelated organ failure (29),
and healthy controls (30)
1992 ACCP/SCCM [1] VWF:Ag tends to differentiate severe
sepsis from sepsis-unrelated organ
failure (P > 0.05)
VWF:Ag not correlated with mortality
Scherpereel et al.,
[53]
2006 90 ICU patients with sepsis (63), SIRS
(7), and healthy controls (20)
1992 ACCP/SCCM [1] VWF higher in sepsis than SIRS (P <
0.02)
VWF correlated with mortality (P =
0.039)
Ware et al., [94] 2001 51 ICU patients with ALI, ARDS (45%
due to sepsis)
Temperature > 38° or < 35°C, systolic blood
pressure < 90 mmHg (or a drop of 20 mm
Hg or more in the systolic blood pressure
from baseline), both present for at least 2 h;
AND a clinically identifiable source of
infection [103]
VWF:Ag higher in patients with
sepsis than those without (P < 0.05)
VWF correlated with mortality (P <
0.005); higher in those with longer
duration of ventilation P < 0.005; not
correlated with illness severity scores
(SAPSII, Lung Injury Score)
Garcia-Fernandez
et al., [92]
2000 80 ICU patients with SIRS and acute
renal failure (40), and healthy
controls (40)
1992 ACCP/SCCM [1] VWF higher in SIRS than controls (P
< 0.001)
Bajaj et al., [97] 1999 60 Ward and ICU patients with ARDS
(18), at risk of ARDS (15), and
healthy controls (27)
Clinical diagnosis of sepsis VWF does not differentiate patients
with ARDS due to sepsis from other
etiologies
VWF higher in ARDS (P < 0.001) and at
risk ARDS (P < 0.01) compared to
controls but did not differ significantly
between these two groups
Kayal et al., [59] 1998 41 ICU patients with severe sepsis or
septic shock (25), ICU controls (7),
healthy controls (9)
1992 ACCP/SCCM [1] VWF:Ag higher in sepsis than
noninfected ICU controls and
healthy controls (P < 0.0001); higher
in septic shock than those without
septic shock (P < 0.01)
VWF:Ag correlated with mortality (P <
0.01); correlated with SAPS and MOF
score (r = 0.57, P < 0.01 for MOF)
Moss et al., [66] 1996 66 ICU patients with sepsis (19), trauma
(36), healthy controls (11)
Clinical diagnosis of sepsis VWF:Ag higher in septic patients
than trauma patients and controls
(both P < 0.001)
Moss et al., [98] 1995 96 Hospitalized patients at risk of ARDS,
including sepsis (30)
Clinical diagnosis of sepsis VWF:Ag not predictive of the
development of ARDS
Lorente et al., [93] 1993 48 ICU patients with septic shock 1992 ACCP/SCCM [1] VWF:Ag not predictive of mortality
Rubin et al., [96] 1990 45 ICU patients with nonpulmonary
sepsis
Clinical diagnosis of sepsis VWF:Ag correlated with mortality (P <
0.005) and ALI (P < 0.01)
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory Distress Syndrome; ED, emergency department; MOF,












not correlated with sepsis severity or survival [95]. Two
other studies found a significant correlation between
VWF and sepsis severity [59,94].
Association with clinical outcome
Four studies looked at its correlation with ALI/ARDS,
with two studies showing its ability to differentiate those
with ALI/ARDS from those without [45,96], and two
studies showing that it is not predictive of ALI/ARDS
[97,98].
Ten of the identified studies presented mortality data,
with six studies showing a significant correlation of
vWF with mortality [45,53,59,90,94,96], with one study
reporting a plasma vWF:Ag of 450% the upper normal
limit predicted death with a sensitivity of 44% and a spe-
cificity of 91% [94]. Four studies did not find a signifi-
cant correlation with mortality [89,91,93,95].
ADAMTS13
Three studies showed that ADAMTS13 is significantly
lower in sepsis than other critically ill nonseptic patients
[89-91]. One study showed significant correlation with
disease severity [91], while a second did not [95]. Three
studies showed ADAMTS13 levels correlated with mor-
tality [89-91], although one study did not find a signifi-
cant correlation [95].
Discussion
We report a comprehensive and exhaustive systematic
review of biomarkers reflecting endothelial activation for
the diagnosis, triage and prognostication of sepsis in
humans. The reviewed literature demonstrates positive
associations between multiple EC-derived molecules and
sepsis, supporting the critical role of EC activation in
the septic response. Multiple other studies also reported
positive associations for mortality and severity of illness,
although these results were less consistent than for sep-
sis per se. Very few studies, however, reported thresh-
olds or receiver operating characteristics that would
establish these molecules as clinically-relevant biomar-
kers in sepsis.
Of the potential biomarkers reviewed, the angiopoeitin-
1/2 system may hold the most promise. Multiple studies
reported consistent associations between elevations in
circulating Ang-2 levels and sepsis in varied samples of
critically ill patients. All studies evaluating Ang-2 used
standard sepsis definitions, with consistent association
between Ang-2 levels and sepsis, as well as relatively con-
sistent associations between Ang-2 and other clinical
outcomes. The strength of association is also supported
in the identified studies by: (1) a demonstrable dose-
response relationship with higher Ang-2 levels in severe
sepsis and organ dysfunction, and increasing with
increasing severity of illness, and (2) a temporal progres-
sion with Ang-2 levels increasing over time in those
patients who developed sepsis and in patients with
increasing severity of sepsis as defined by SIRS, sepsis
and septic shock. Unfortunately, no studies provided a
cut point or threshold that would make Ang-2 clinically
useful as a biomarker in the diagnosis or stratification of
patients presenting with presumed sepsis.
One general limitation with all of the identified studies
is the lack of standardized assays for the studied
Table 10 Studies evaluating ADAMTS13






Claus et al., [89] 2009 63 ICU patients with severe sepsis (11),
non-elective cardiac surgery (22),
elective cardiac surgery as ICU





lower in sepsis than
ICU reference group (P
< 0.001)
ADAMTS13 activity correlated with
mortality (P < 0.05)
Bockmeyer
et al., [90]
2008 57 ICU patients with sepsis (11), non-
elective cardiac surgery (22), and
elective cardiac surgery as ICU
controls (24)
Not specified ADAMTS13 activity
lower in sepsis than
ICU controls
(P < 0.01)
ADAMTS13 activity correlated with
mortality (P < 0.01)
Hovinga et al.,
[95]
2007 80 Medical and surgical ICU patients
with severe sepsis or septic shock




lower in sepsis than
healthy controls (P <
0.001)
ADAMTS13 activity not correlated with
disease severity, organ dysfunction, or
mortality
Martin et al., [91] 2007 89 ICU patients with severe sepsis (30),
sepsis-unrelated organ failure (29),




lower in severe sepsis
than sepsis-unrelated
organ failure
(P < 0.05) and healthy
controls (P < 0.05)
ADAMTS13 activity correlated with
APACHE II (r = -0.66, P < 0.0001),
number of organ failures (r = -0.66,
P < 0.0001), and mortality (P = 0.02 by
log rank test)
ACCP, American College of Chest Physicians; ALI, Acute Lung Injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, Acute Respiratory
Distress Syndrome; ED, emergency department; MOF, Multiple Organ Failure; SAPS, Simplified Acute Physiology Score; SCCM, Society of Critical Care Medicine;
SIRS, Systemic Inflammatory Response Syndrome; SOFA, Sequential Organ Failure Assessment
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molecules. Very few studies reported threshold values
for prognostic analysis or receiver operating characteris-
tics of the potential biomarkers. Furthermore, almost all
studies were either single centre or single laboratory,
and most assays were non-standardized ELISAs, and
thus the absolute values reported in each study may
vary according to the type of assay, as well as the type
of sample used (for example, plasma vs. serum). These
issues led to important limitations in the generalizability
and strength of inference that can be drawn from the
identified studies. Where possible, we have reported
absolute values in the tables to allow readers to appreci-
ate the scope of variation, as well as absolute differences
in levels between groups.
There are several limitations to our study. We
searched for known endothelial-derived markers by
name, and it is possible that other novel markers were
missed. We attempted to address this limitation by
hand-searching the reference list of identified studies to
include all relevant studies of selected endothelial-
derived markers. Many of the identified publications are
single-centre studies or retrospective analyses of pre-
viously collected specimens, which limit generalizability
to other jurisdictions and populations. As previously
mentioned, lack of standardization in the reported
assays makes quantitative comparison of a biomarker
across studies impossible, and thus we can only report
similarities in the direction and relative magnitude of
association across studies.
The identified studies were most commonly small pro-
spective or retrospective cohort studies evaluating levels
of a potential biomarker in patients with sepsis and a
comparative control group. Almost all studies used
established consensus criteria for the definition of sepsis
to limit misclassification of patients. There was signifi-
cant heterogeneity in patient populations across studies,
however, including patients with presumed sepsis identi-
fied in any one of the emergency department, medical
ward and medical, surgical and trauma intensive care
units. It is conceivable that the receiver operating char-
acteristics of any given biomarker may vary according to
the differential inflammatory state, concurrent injuries
and pathophysiology of these different patient groups.
If EC-derived biomarkers are to become clinically use-
ful, future work will require standardization of analytical
techniques and rigorous evaluation of receiver operating
characteristics to define the role and reliability of these
molecules. Although some recent studies reported recei-
ver operating characteristics or threshold biomarker
levels, the lack of standard assays limits the interpreta-
tion and clinical utility of these efforts. Future work
must include: (1) the description of the operating char-
acteristics of biomarkers, (2) the use of explicitly defined
threshold serum levels, (3) measured with a standardized
assay.
It may be impossible to achieve the high degree of
sensitivity and specificity required for clinical diagnosis
with a single biomarker assay, and a multiplexed combi-
nation of markers may be necessary to improve predic-
tive value and clinical utility of biomarkers. Careful
selection and combinations of biomarkers with relative
specificity to disease states (for example, the observed
association between Ang-2 and ARDS/pulmonary leak,
or the differential association of sVCAM and sE-Selectin
in fungal sepsis) would be one way of improving the
clinical utility of these novel molecules. Following iden-
tification of useful serum biomarker thresholds with
standard assays, we speculate that evaluation of multi-
plexed biomarker panels may prove useful as a diagnos-
tic strategy.
Given the epidemiologic rise of sepsis in both the
developed [99] and developing world [100], novel diag-
nostics and therapeutics for sepsis are urgently needed,
and endothelial-derived biomarkers will likely play a
crucial role.
Conclusions
We report a systematic review of the published litera-
ture and findings that multiple molecules reflecting
endothelial activation are correlated with the presence
of sepsis in humans. We also found variable degrees of
correlation between biomarkers and other clinical out-
comes. The clinical utility or application of these mole-
cules as biomarkers in sepsis, however, is limited by a
lack of standardization in analytical assays, a lack of
data regarding receiver operating characteristics and, in
the few cases where thresholds have been reported, a
lack of validation in representative patient populations.
Key messages
• Multiple molecules reflecting endothelial activation
are correlated with the presence of sepsis in humans
and other clinically important outcomes.
• The clinical utility or application of these mole-
cules as biomarkers in sepsis; however, is limited by
a lack of standardization in analytical assays, a lack
of data regarding receiver operating characteristics
and a lack of validation.
• The consistent association with sepsis, demon-
strable dose-response relationship, and temporal
progression in patients who develop sepsis make
Angiopoietin-2 an attractive potential biomarker in
sepsis.
• Future research should focus on standardization of
assays and identification of cut points or thresholds
that make biomarkers clinically useful in the
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diagnosis or stratification of patients presenting with
presumed sepsis.
• Evaluation of multiplexed panels with biomarkers
of differential response characteristics may prove
useful as a diagnostic strategy.
Additional material
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